Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.

Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.

As part of a wide-ranging discussion of its biosimilars business as it reported nine-month results, Sandoz has revealed that it is considering launching its Tysabri (natalizumab) biosimilar Tyruko “at risk” in the US, while also providing an update on its progress with adalimumab as well as certain key pipeline assets.

Reporting its first results as a standalone company, Sandoz has delivered double-digit growth in biosimilars for the first nine months of 2023, helping to lift the overall business as generics also enjoyed a more modest increase.